Daily Sepsis Research Analysis
Three papers stand out today: a rigorous mechanistic study reveals that HDL suppresses LPS-driven IL-1β via SR-B1 and that CETP inhibition improves survival in experimental endotoxemia; a nationwide Danish cohort links early-onset neonatal sepsis/meningitis to increased childhood epilepsy risk; and an observational MIMIC-IV analysis suggests early statin use in sepsis-associated AKI is associated with lower 28- and 90-day mortality. Together they span pathophysiology, long-term outcomes, and pra
Summary
Three papers stand out today: a rigorous mechanistic study reveals that HDL suppresses LPS-driven IL-1β via SR-B1 and that CETP inhibition improves survival in experimental endotoxemia; a nationwide Danish cohort links early-onset neonatal sepsis/meningitis to increased childhood epilepsy risk; and an observational MIMIC-IV analysis suggests early statin use in sepsis-associated AKI is associated with lower 28- and 90-day mortality. Together they span pathophysiology, long-term outcomes, and pragmatic repurposing.
Research Themes
- Lipid–immune crosstalk and therapeutic targeting in sepsis
- Long-term neurologic sequelae after early-onset neonatal sepsis
- Drug repurposing (statins) in sepsis-associated acute kidney injury
Selected Articles
1. High-density lipoprotein attenuates lipopolysaccharide-induced IL-1β activation via scavenger receptor class B type 1.
This mechanistic study shows that HDL suppresses LPS-driven IL-1β via SR-B1-dependent internalization and degradation of LPS, and that CETP inhibition (anacetrapib) raises HDL, dampens inflammation, and improves survival in murine endotoxemia. It elucidates a clear lipid–innate immune pathway with therapeutic potential.
Impact: Reveals a novel, targetable mechanism linking HDL/SR-B1 to endotoxin handling and inflammatory control in sepsis, supported by survival benefit with a clinically developed CETP inhibitor.
Clinical Implications: Although preclinical, findings support testing HDL-raising strategies (e.g., CETP inhibitors, HDL mimetics) or SR-B1 pathway modulation as adjunctive therapies in endotoxemia/sepsis, with caution about translating from endotoxemia to clinical sepsis.
Key Findings
- HDL inhibited LPS-induced IL-1β activation in a mouse model of sepsis.
- SR-B1 activity was required; SR-B1 knockdown reduced macrophage IL-1β production and SR-B1 internalization trafficked via endosome–lysosome pathways facilitating LPS degradation.
- CETP inhibition increased HDL, enhanced anti-inflammatory effects, reduced hepatic and pulmonary injury, and improved survival after LPS challenge.
Methodological Strengths
- Integrative mechanistic approach with in vitro macrophage studies and in vivo murine endotoxemia outcomes
- Pharmacologic validation using a CETP inhibitor (anacetrapib) demonstrating survival benefit and tissue protection
Limitations
- Endotoxemia model may not capture the complexity of clinical, polymicrobial sepsis
- Translational uncertainty regarding dose, timing, and safety of CETP inhibition in septic humans
Future Directions: Test HDL-raising or SR-B1-targeting strategies in polymicrobial sepsis models and early-phase clinical trials; define pharmacodynamics, optimal timing, and biomarkers (e.g., IL-1β suppression) for patient selection.
Sepsis is the dysregulated immune response to an infection and is a leading cause of mortality. Low levels of high-density lipoprotein (HDL) cholesterol are associated with increased risk of death from sepsis, and increasing levels of HDL by inhibition of cholesteryl ester transfer protein (CETP) has been shown to decrease mortality in mouse models of sepsis. The objective of this study was to investigate the cellular mechanisms by which CETP inhibition and HDL lead to improved survival during sepsis. We found that HDL inhibits lipopolysaccharide (LPS)-induced activation of IL-1β in a mouse model of sepsis. The activation of IL-1β was dependent on the activity of scavenger receptor class B type 1 (SR-B1), and knockdown of SR-B1 significantly attenuated LPS-induced production of IL-1β in macrophages. Additionally, we found that LPS-induced SR-B1 internalization occurs through the endosome-lysosome pathway, which is also likely responsible for LPS degradation in the macrophages. Furthermore, we revealed that raising HDL by CETP inhibition markedly enhanced HDL-mediated anti-inflammatory effects in response to LPS stimulation, and these effects were not due to CETP itself but rather were HDL-dependent. Finally, we show that pharmacological inhibition of CETP significantly improved endotoxemia-induced mortality by inhibiting IL-1β production in the liver and circulation after LPS injection. Pathologically, CETP inhibition attenuated LPS-induced diffuse alveolar damage and hepatocyte necrosis, which may contribute to the improved mortality in mice treated with the CETP inhibitor anacetrapib. Taken together, our findings uncover a cellular mechanism by which HDL attenuates LPS-induced pro-inflammatory response via SR-B1-mediated LPS degradation.
2. Early-Onset Neonatal Infection and Epilepsy in Children.
In a nationwide Danish cohort of 981,869 late-preterm/term children, early-onset neonatal sepsis was associated with nearly doubled risk of epilepsy, and early-onset meningitis carried a markedly higher risk (~10-fold). Findings support long-term neurologic surveillance after neonatal invasive infections.
Impact: Establishes robust, population-level evidence linking early neonatal invasive infection with later epilepsy, quantifying risk across diagnostic and culture-confirmed definitions.
Clinical Implications: Supports counseling and structured neurodevelopmental follow-up for infants with early-onset sepsis/meningitis; motivates prevention efforts (e.g., maternal GBS strategies) and trials aimed at neuroprotection.
Key Findings
- Among 981,869 children, early-onset sepsis was associated with an adjusted HR of 1.85 (95% CI 1.60–2.13) for epilepsy.
- Culture-positive sepsis increased epilepsy risk (IRR 2.70; 95% CI 1.08–5.56).
- Meningitis conferred the highest risk: diagnosed IRR 9.85 (95% CI 5.52–16.27); culture-confirmed IRR 16.04 (95% CI 5.21–37.46).
Methodological Strengths
- Nationwide, population-based design with very large sample and long follow-up
- Multivariable Cox modeling and analyses across diagnostic and culture-confirmed definitions
Limitations
- Registry-based observational design with potential residual confounding and misclassification
- Limited numbers of culture-confirmed cases reduce precision for some subgroup estimates
Future Directions: Evaluate neuroprotective strategies and targeted follow-up pathways for infants with early-onset infections; investigate mechanistic links between neonatal inflammation and epileptogenesis.
IMPORTANCE: Epilepsy is a common neurological disorder in childhood. It remains unclear whether early-onset sepsis is associated with epilepsy and to what extent early-onset meningitis may contribute to its development. OBJECTIVE: To study the association between early-onset neonatal infection and childhood epilepsy. DESIGN, SETTING, AND PARTICIPANTS: Nationwide, population-based, register-based cohort study of all Danish live-born singletons with at least 35 completed gestational weeks at birth without major congenital anomalies in Denmark between 1997 and 2013 with follow-up until 2021 or age 18 years, whichever came first. Data were analyzed from February 2024 to January 2025. EXPOSURES: Early-onset infection was defined as an invasive bacterial infection during the first week of life. Diagnosed infection was defined by diagnostic codes of sepsis or meningitis, while culture-positive infection only included those with bacterial pathogens cultured from blood or cerebrospinal fluid. MAIN OUTCOMES AND MEASURES: Epilepsy was defined as a hospital diagnosis or at least 2 redeemed prescriptions of antiepileptic medication. The association between diagnosed sepsis and epilepsy was investigated with multivariable Cox regression to estimate adjusted hazard ratios (HR) with 95% CIs. Associations for the remaining definitions of infection were investigated using person-time incidence rate ratios (IRR). RESULTS: Among 981 869 children, the median (IQR) gestational age was 40 (39-41) weeks, 501 615 (51%) were male, 8154 (0.8%) were diagnosed with sepsis, and 152 (<0.1%) were diagnosed with meningitis. Of these, 257 children had culture-positive sepsis and 32 had culture-positive meningitis. The incidence rate of epilepsy was 1.6 per 1000 person-years for children with diagnosed sepsis compared with 0.9 per 1000 person-years for children without an infection, resulting in an adjusted HR of 1.85 (95% CI, 1.60-2.13). Culture-positive sepsis was also associated with an increased risk of epilepsy (IRR, 2.70; 95% CI, 1.08-5.56), while the highest risks were observed in children with meningitis both diagnosed (IRR, 9.85; 95% CI, 5.52-16.27) and verified by culture (IRR, 16.04; 95% CI, 5.21-37.46). CONCLUSIONS AND RELEVANCE: In this nationwide cohort study, early-onset neonatal sepsis was associated with an approximately 2-fold increased risk of childhood epilepsy. As expected, early-onset meningitis was associated with an even higher risk of epilepsy with an approximately 10-fold increase.
3. The impact of early use of statin in sepsis patients with acute kidney injury: a study based on MIMIC-IV.
Using MIMIC-IV, early statin exposure (within 48 h) in SA-AKI was associated with lower 28- and 90-day mortality and better renal recovery despite longer ICU stay; effects were consistent across statin types and stronger among patients with hypertension.
Impact: Provides large-scale, propensity-matched real-world evidence suggesting a mortality benefit of early statins in SA-AKI, motivating pragmatic RCTs and patient selection strategies.
Clinical Implications: Consideration of early statin continuation/initiation in SA-AKI may be reasonable pending RCTs, especially in hypertensive patients, while monitoring for potential adverse effects and acknowledging confounding in observational data.
Key Findings
- Early statin use within 48 hours was associated with reduced 28-day and 90-day mortality after propensity score matching.
- Renal function recovery improved with early statins, though ICU length of stay was longer.
- Benefits were observed across statin types and were more pronounced in patients with hypertension.
Methodological Strengths
- Large sample with propensity score matching and time-dependent Cox regression
- Multiple outcome assessments (28-/90-day mortality, renal recovery, ICU length of stay) and subgroup analyses
Limitations
- Retrospective single-database design with potential residual confounding and indication bias
- ICU stay prolongation raises questions about survivorship bias and care intensity differences
Future Directions: Conduct randomized trials of early statins in SA-AKI, define optimal timing/dosing, and identify phenotypes (e.g., hypertensive patients) most likely to benefit.
OBJECTIVE: Sepsis-associated acute kidney injury (SA-AKI) is a prevalent and serious condition in the ICU. The efficacy of statin in these patients remains unclear. The purpose of this study was to investigate the impact of the early use of statin on the prognosis of SA-AKI patients. METHODS: The patients included in this study were derived from the MIMIC-IV database. Patients were divided into the non-statin and statin groups based on whether they received statin within 48 h of admission. After propensity score matching, time-dependent Cox regression analysis was used to evaluate the relationship between the early use of statin and mortality. The relationship between treatment and the recovery of renal function was assessed by logistic analysis, and the association between the use of statin and length of ICU stay was evaluated by the negative binomial regression model. RESULTS: A total of 11,667 patients were included in the study. After propensity score matching, there were 1,585 patients in each group, and the baselines between the two groups were comparable. Although statin use was associated with prolonged ICU stay, it was significantly linked to reduced 28-day and 90-day mortality and improved renal function recovery. Subgroup analysis indicated that the protective effect of early statin use was more effective in patients with hypertension. In comparison with the non-statin group, the use of different types of statin were associated with reduced 28-day mortality in sepsis patients with AKI. Compared with the rosuvastatin group, there was no significant difference in reducing the risk of mortality among other types of statins. CONCLUSION: In sepsis patients with AKI, the early use of statin was associated with a reduction in 28-day and 90-day mortality. The early use of statin plays a protective role in patients with SA-AKI.